Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
Objective There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. However, in patients with advanced ICC, the safety and effi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2022.2048416 |
| _version_ | 1819121148271525888 |
|---|---|
| author | Min Deng Shaohua Li Qiaoxuan Wang Rongce Zhao Jingwen Zou Wenping Lin Jie Mei Wei Wei Rongping Guo |
| author_facet | Min Deng Shaohua Li Qiaoxuan Wang Rongce Zhao Jingwen Zou Wenping Lin Jie Mei Wei Wei Rongping Guo |
| author_sort | Min Deng |
| collection | DOAJ |
| description | Objective There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. However, in patients with advanced ICC, the safety and efficacy of anti-PD-1 agents remain unclear.Methods Forty-two advanced ICC patients treated with anti-PD-1 agents from August 2018 to December 2020 were retrospectively analyzed. Tumour response, overall survival (OS), progression-free survival (PFS), and time to tumour progression (TTP) were evaluated. Adverse events were also recorded.Results The median duration of follow-up was 12.1 months, and the median time of treatment was 6.7 months for all patients. The median OS, median PFS, and median TTP for the whole cohort were 19.3 months, 11.6 months, and 11.6 months, respectively. The overall response rate (ORR) and disease control rate (DCR) for the whole cohort were 23.8% and 85.7%, respectively. Of the 42 evaluable individuals, two (4.8%) had hyperprogressive disease. The most common adverse events (AEs) were pain (n = 6; 14.3%), anorexia (n = 4; 9.5%), hypertension (n = 4; 9.5%), pyrexia (n = 3; 7.1%), cough (n = 3; 7.1%), and hypothyroidism (n = 3; 7.1%). The median OS of patients with albumin-bilirubin (ALBI) grade 1 was longer than that of patients with ALBI grade 2 (19.3 months vs. 14.7 months). The median PFS did not show a significant difference between ALBI grade 1 and grade 2 patients (13.6 months vs. 6.9 months).Conclusions PD‐1‐targeted immunotherapy showed promising efficacy and safety in advanced ICC patients.Key messagesPD-1-targeted immunotherapy is a safe and effective treatment for advanced ICC patients.This study provides therapeutic strategy for advanced ICC patients. |
| first_indexed | 2024-12-22T06:31:57Z |
| format | Article |
| id | doaj.art-96f18083a98b42cfae1be5e063578313 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-12-22T06:31:57Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-96f18083a98b42cfae1be5e0635783132022-12-21T18:35:41ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602022-12-0154180381110.1080/07853890.2022.2048416Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapyMin Deng0Shaohua Li1Qiaoxuan Wang2Rongce Zhao3Jingwen Zou4Wenping Lin5Jie Mei6Wei Wei7Rongping Guo8Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, ChinaObjective There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. However, in patients with advanced ICC, the safety and efficacy of anti-PD-1 agents remain unclear.Methods Forty-two advanced ICC patients treated with anti-PD-1 agents from August 2018 to December 2020 were retrospectively analyzed. Tumour response, overall survival (OS), progression-free survival (PFS), and time to tumour progression (TTP) were evaluated. Adverse events were also recorded.Results The median duration of follow-up was 12.1 months, and the median time of treatment was 6.7 months for all patients. The median OS, median PFS, and median TTP for the whole cohort were 19.3 months, 11.6 months, and 11.6 months, respectively. The overall response rate (ORR) and disease control rate (DCR) for the whole cohort were 23.8% and 85.7%, respectively. Of the 42 evaluable individuals, two (4.8%) had hyperprogressive disease. The most common adverse events (AEs) were pain (n = 6; 14.3%), anorexia (n = 4; 9.5%), hypertension (n = 4; 9.5%), pyrexia (n = 3; 7.1%), cough (n = 3; 7.1%), and hypothyroidism (n = 3; 7.1%). The median OS of patients with albumin-bilirubin (ALBI) grade 1 was longer than that of patients with ALBI grade 2 (19.3 months vs. 14.7 months). The median PFS did not show a significant difference between ALBI grade 1 and grade 2 patients (13.6 months vs. 6.9 months).Conclusions PD‐1‐targeted immunotherapy showed promising efficacy and safety in advanced ICC patients.Key messagesPD-1-targeted immunotherapy is a safe and effective treatment for advanced ICC patients.This study provides therapeutic strategy for advanced ICC patients.https://www.tandfonline.com/doi/10.1080/07853890.2022.2048416Intrahepatic cholangiocarcinomaimmunotherapyPD-1real-worldoutcome |
| spellingShingle | Min Deng Shaohua Li Qiaoxuan Wang Rongce Zhao Jingwen Zou Wenping Lin Jie Mei Wei Wei Rongping Guo Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy Annals of Medicine Intrahepatic cholangiocarcinoma immunotherapy PD-1 real-world outcome |
| title | Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy |
| title_full | Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy |
| title_fullStr | Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy |
| title_full_unstemmed | Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy |
| title_short | Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy |
| title_sort | real world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein 1 targeted immunotherapy |
| topic | Intrahepatic cholangiocarcinoma immunotherapy PD-1 real-world outcome |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2022.2048416 |
| work_keys_str_mv | AT mindeng realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT shaohuali realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT qiaoxuanwang realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT rongcezhao realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT jingwenzou realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT wenpinglin realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT jiemei realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT weiwei realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy AT rongpingguo realworldoutcomesofpatientswithadvancedintrahepaticcholangiocarcinomatreatedwithprogrammedcelldeathprotein1targetedimmunotherapy |